Abstract:
Our study explores the development of collagen membranes with integrated minocycline or irinotecan, targeting applications in tissue engineering and drug delivery systems. Type I collagen, extracted from bovine skin using advanced fibril-forming technology, was crosslinked with glutaraldehyde to create membranes. These membranes incorporated minocycline, an antibiotic, or irinotecan, a chemotherapeutic agent, in various concentrations. The membranes, varying in drug concentration, were studied by water absorption and enzymatic degradation tests, demonstrating a degree of permeability. We emphasize the advantages of local drug delivery for treating high-grade gliomas, highlighting the targeted approach\'s efficacy in reducing systemic adverse effects and enhancing drug bioavailability at the tumor site. The utilization of collagen membranes is proposed as a viable method for local drug delivery. Irinotecan\'s mechanism, a topoisomerase I inhibitor, and minocycline\'s broad antibacterial spectrum and inhibition of glial cell-induced membrane degradation are discussed. We critically examine the challenges posed by the systemic administration of chemotherapeutic agents, mainly due to the blood-brain barrier\'s restrictive nature, advocating for local delivery methods as a more effective alternative for glioblastoma treatment. These local delivery strategies, including collagen membranes, are posited as significant advancements in enhancing therapeutic outcomes for glioblastoma patients.
摘要:
我们的研究探索了整合米诺环素或伊立替康的胶原蛋白膜的发育,组织工程和药物递送系统中的靶向应用。I型胶原蛋白,使用先进的原纤维形成技术从牛皮中提取,与戊二醛交联以产生膜。这些膜掺入了米诺环素,抗生素,或者伊立替康,化疗药物,在各种浓度。膜,药物浓度不同,通过吸水和酶降解试验进行了研究,表现出一定程度的渗透性。我们强调局部给药治疗高级别胶质瘤的优势,强调靶向方法在减少全身不良反应和提高肿瘤部位药物生物利用度方面的功效。提出了利用胶原膜作为局部药物递送的可行方法。伊立替康的机制,拓扑异构酶I抑制剂,讨论了米诺环素的广谱抗菌作用和抑制胶质细胞诱导的细胞膜降解的作用。我们严格地研究了化疗药物的全身给药所带来的挑战,主要是由于血脑屏障的限制性,提倡局部给药方法作为胶质母细胞瘤治疗的更有效替代方法。这些本地交付策略,包括胶原膜,被认为是提高胶质母细胞瘤患者治疗效果的重大进展。